<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>RENAGELÂ - sevelamer hydrochlorideÂ tabletÂ </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use Renagel safely and
    effectively. See full prescribing information for Renagel.  Renagel (sevelamer hydrochloride) Tablet for Oral use  Initial U.S. Approval: 2000</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p> RENAGEL<span class="Sup">Â®</span><a href="#footnote-1">1</a>Â (sevelamer
hydrochloride) is indicated for the control of serum phosphorus in patients with
<span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> (CKD) on dialysis. The safety and efficacy of Renagel in CKD
patients who are not on dialysis have not been studied. </p>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p>
Â 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd> Â Â Renagel is a
Registered Trademark of Genzyme Corporation.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p><span class="Italics"><span class="Emphasis"> Patients Not Taking a Phosphate Binder</span></span>. The recommended starting dose of Renagel is 800 to 1600 mg, which can be
administered as oneÂ or two 800 mg Renagel<span class="Sup">Â®</span> Tablets or two
to four 400 mg Renagel<span class="Sup">Â®</span> Tablets, withÂ meals based on
serum phosphorus level. <a href="#dc96a9a6-295a-4c09-8877-2c1f8d30952e"> Table
1</a> provides recommended starting doses of Renagel for patients not taking
a phosphate binder. </p>
<a name="dc96a9a6-295a-4c09-8877-2c1f8d30952e"></a><table>
<caption><span>Table 1. Starting Dose for DialysisÂ Patients Not Taking a Phosphate
Binder</span></caption>
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="1"><span class="Bold"><span class="Emphasis"> Serum Phosphorus </span></span></th>
<th align="center" colspan="1">
<span class="Bold"><span class="Emphasis"> Renagel</span></span><span class="Bold"><span class="Emphasis"><span class="Sup">Â®</span></span></span><span class="Bold"><span class="Emphasis"> 800 mg </span></span>
</th>
<th align="center" colspan="1">
<span class="Bold"><span class="Emphasis"> Renagel</span></span><span class="Bold"><span class="Emphasis"><span class="Sup">Â®</span></span></span><span class="Bold"><span class="Emphasis"> 400 mg </span></span>
</th>
</tr>
<tr>
<td align="center"><p class="First">&gt; 5.5 and &lt; 7.5 mg/dL</p></td>
<td align="center"><p class="First">1 tablet three times daily with meals</p></td>
<td align="center"><p class="First">2 tablets three times daily with meals</p></td>
</tr>
<tr>
<td align="center"><p class="First">â‰¥ 7.5 and &lt; 9.0 mg/dL</p></td>
<td align="center"><p class="First">2 tablets three times daily with meals</p></td>
<td align="center"><p class="First">3 tablets three times daily with meals</p></td>
</tr>
<tr class="Last">
<td align="center"><p class="First">â‰¥ 9.0 mg/dL</p></td>
<td align="center"><p class="First">2 tablets three times daily with meals</p></td>
<td align="center"><p class="First">4 tablets three times daily with meals</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="Emphasis"> Patients Switching From Calcium Acetate</span></span>. In a study in 84 CKD patients on hemodialysis, a similar reduction in
serum phosphorus was seen with equivalent doses (approximately mg for mg) of Renagel
and calcium acetate. <a href="#d93597ec-8962-496d-b5a9-4561f84e9427"> Table
2</a> gives recommended starting doses of Renagel based on a
patientâ€™s current calcium acetate dose. </p>
<a name="d93597ec-8962-496d-b5a9-4561f84e9427"></a><table>
<caption><span>Table 2. Starting Dose for Dialysis Patients Switching From Calcium Acetate
to Renagel</span></caption>
<col align="center" span="1">
<col align="center" span="1">
<col align="center" span="1">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="1"><span class="Bold"><span class="Emphasis"> Calcium Acetate 667 mg<br>(Tablets per meal)
</span></span></th>
<th align="center" colspan="1">
<span class="Bold"><span class="Emphasis"> Renagel<span class="Sup">Â®</span> 800 </span></span><span class="Bold"><span class="Emphasis"> mg<br>(Tablets per meal) </span></span>
</th>
<th align="center" colspan="1">
<span class="Bold"><span class="Emphasis"> Renagel</span></span><span class="Bold"><span class="Emphasis"><span class="Sup">Â®</span></span></span><span class="Bold"><span class="Emphasis"> 400 </span></span><span class="Bold"><span class="Emphasis"> mg </span></span><span class="Bold"><span class="Emphasis"><br>(Tablets per meal) </span></span>
</th>
</tr>
<tr>
<td align="center"><p class="First">1 tablet</p></td>
<td align="center"><p class="First">1 tablet</p></td>
<td align="center"><p class="First">2 tablets </p></td>
</tr>
<tr>
<td align="center"><p class="First">2 tablets</p></td>
<td align="center"><p class="First">2 tablets</p></td>
<td align="center"><p class="First">3 tablets </p></td>
</tr>
<tr class="Last">
<td align="center"><p class="First">3 tablets</p></td>
<td align="center"><p class="First">3 tablets</p></td>
<td align="center"><p class="First">5 tablets </p></td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="Emphasis"> Dose Titration for All Patients Taking
Renagel</span></span>. Dosage should be adjusted based on the serum phosphorus concentration with
a goal of lowering serum phosphorus to 5.5 mg/dL or less. The dose may be increased or
decreased by one tablet per meal at two week intervals as necessary. <a href="#e6083c2f-981c-4742-aef3-40abe7e9edd4"> Table 3</a> gives a dose
titration guideline. The average dose in a Phase 3 trial designed to lower serum
phosphorus to 5.0 mg/dL or less was approximately three Renagel 800 mg tablets per
meal. The maximum average daily Renagel dose studied was 13 grams. </p>
<a name="e6083c2f-981c-4742-aef3-40abe7e9edd4"></a><table>
<caption><span>Table 3. Dose Titration Guideline</span></caption>
<col align="left" span="1">
<col align="left" span="1">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">
<span class="Bold"><span class="Emphasis"> Serum Phosphorus </span></span><br>
</th>
<th align="left" colspan="1">
<span class="Bold"><span class="Emphasis"> Renagel<span class="Sup">Â®</span> Dose </span></span><br>
</th>
</tr>
<tr>
<td align="left"><p class="First">&gt;5.5 mg/dL</p></td>
<td align="left"><p class="First">Increase 1 tablet per meal at 2 week intervals</p></td>
</tr>
<tr>
<td align="left"><p class="First">3.5Â - 5.5 mg/dL</p></td>
<td align="left"><p class="First">Maintain current dose</p></td>
</tr>
<tr class="Last">
<td align="left"><p class="First">&lt;3.5 mg/dL</p></td>
<td align="left"><p class="First">Decrease 1 tablet per meal</p></td>
</tr>
</tbody>
</table>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p>800 mg and 400 mg Tablets.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>Renagel is contraindicated in patients with <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<ul><li> Serious cases of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, and perforation have been associated with sevelamer use, some requiring hospitalization and surgery. (<a href="#b6a267e2-62e5-4922-a258-f27bb2ce7875">5.1</a>) </li></ul>
<p>
Â 
</p>
<p></p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> and esophageal tablet retention have been reported in association with
use of the tablet formulation of sevelamer, some requiring hospitalization and intervention. Consider 
using sevelamer suspension in patients with a history of <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">swallowing disorders</span>.<br><br> Cases of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span> 
and perforation have also been reported with sevelamer use.<br><br> Patients with <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">swallowing disorders</span>,
severe gastrointestinal (GI) motility disorders including severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, or major GI tract surgery 
were not included in the Renagel clinical studies.</p>
<p>
Â 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> and chloride levels should be monitored.</p>
<p>
Â 
</p>
<p></p>
<p>In preclinical studies in rats and dogs, sevelamer hydrochloride reduced
vitamins D, E, and K (coagulation parameters) and folic acid levels at doses of
6-10 times the recommended human dose.Â In short-term clinical trials,
there was no evidence of reduction in serum levels of vitamins.Â  However,
inÂ a one-year clinical trial, 25-hydroxyvitamin D (normal range 10 to 55
ng/mL) fell from 39 Â± 22 ng/mL to 34 Â± 22 ng/mL (p&lt;0.01)
with sevelamer hydrochloride treatment.Â Most (approximately 75%)
patients inÂ sevelamer hydrochlorideÂ clinical trials received
vitamin supplements, which is typical of patients on dialysis.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<ul>
<li> The most common reasons for discontinuing treatment were gastrointestinal
adverse reactions. (<a href="#ac6c2ee2-f040-4dd1-969f-65b720d1e830">6.1</a>) </li>
<li> In a parallel design study, ofÂ 12 weeks duration, treatment
emergent adverseÂ reactions to RenagelÂ Tablets in peritoneal
dialysis patients included <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (12%), <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> (8%),
<span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (5%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (5%), <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>
(4%),Â <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (4%), <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdominal distension</span> (3%),
<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (3%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (3%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (3%), and
<span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> (3%). (<a href="#ac6c2ee2-f040-4dd1-969f-65b720d1e830">6.1</a>) </li>
<li> Similar reactions at similar rates occurred in hemodialysis and peritoneal
dialysis patients. (<a href="#ac6c2ee2-f040-4dd1-969f-65b720d1e830">6.1</a>) </li>
<li> Cases of <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span> and, less commonly, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">bowel obstruction</span>, and
<span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">bowel perforation</span> have been reported. (<a href="#df163be9-d042-4ccd-9d79-e8823244bc15">6.2</a>) </li>
</ul>
<p><span class="Bold"><span class="Emphasis">To report SUSPECTED ADVERSE REACTIONS, contact
Genzyme Corporation at 1-800-847-0069 and Â or FDA at 1-800-FDA-1088
or www.fda.gov/medwatch</span></span></p>
<p>
Â 
</p>
<p></p>
<p>Because clinical trials are conducted under widely varying conditions,
adverse reaction rates observed in the clinical trials of a drug can not be
directly compared to rates in the clinical trials of another drug and may not
reflect the rates observed in practice.</p>
<p>In a parallel design study of sevelamer hydrochloride with treatment
duration of 52 weeks, adverse reactions reported for sevelamer hydrochloride
(n=99) were similar to those reported for the active-control group (n=101).
Overall adverse reactions among those treated with sevelamer hydrochloride
occurring in &gt; 5% of patients included: <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> (22%),
<span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (20%), <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (19%), <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span> (16%), abdominal
<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (9%), <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span> (8%) and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> (8%). A total
of 27 patients treated with sevelamer and 10 patients treated with comparator
withdrew from the study due to adverse reactions.</p>
<p>Based on studies of 8-52 weeks, the most common reason for withdrawal
from Renagel was gastrointestinal adverse reactions (3-16%).</p>
<p>In one hundred and forty-three peritoneal dialysis patients studied
forÂ 12 weeks most adverse reactions were similar to adverse reactions
observed in hemodialysis patients. The most frequently occurring treatment
emergent serious adverse reaction was <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> (8 reactions in 8 patients
[8%] in the sevelamer group and 2 reactions in 2 patients [4%] on
active-control). Thirteen patients (14%) in the sevelamer group and 9
patients (20%) in the active-control group discontinued, mostly for
gastrointestinal adverse reactions. Patients on peritoneal dialysis should be
closely monitored to ensure the reliable use of appropriate aseptic technique with
the prompt recognition and management of any signs and symptoms associated with
<span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>.</p>
<p>
Â 
</p>
<p></p>
<p> The following adverse reactions have been identified during
post-approval use of sevelamer hydrochloride (Renagel<span class="Sup">Â®</span>):
<span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span> and uncommon cases of <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>,
<span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, and <span class="product-label-link" type="condition" conceptid="193242" conceptname="Perforation of intestine">intestinal perforation</span>. Appropriate medical management
should be given to patients who develop <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> or have worsening of existing
<span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> to avoid severe complications. </p>
<p>Because these reactions are reported voluntarily from a population of
uncertain size, it is not always possible to estimate their frequency or to
establish a causal relationship to drug exposure.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<p>Renagel has been studied in human drug-drug interaction studies with
ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron.</p>
<p>
Â 
</p>
<p></p>
<p>In a study of 15 healthy subjects, a co-administered single dose of 7
Renagel capsules (approximately 2.8 g) decreased the bioavailability of
ciprofloxacin by approximately 50%.</p>
<p>
Â 
</p>
<p></p>
<p>In 19 healthy subjects receiving 6 Renagel capsules three times a day
with meals for 2 days, Renagel did not alter the pharmacokinetics of a single dose
of digoxin.</p>
<p>
Â 
</p>
<p></p>
<p>In 14 healthy subjects receiving 6 Renagel capsules three times a day
with meals for 2 days, Renagel did not alter the pharmacokinetics of a single dose
of warfarin.</p>
<p>
Â 
</p>
<p></p>
<p>In 28 healthy subjects a single dose of 6 Renagel capsules did not alter
the pharmacokinetics of a single dose of enalapril.</p>
<p>
Â 
</p>
<p></p>
<p>In 31 healthy subjects a single dose of 6 Renagel capsules did not alter
the pharmacokinetics of a single dose of metoprolol.</p>
<p>
Â 
</p>
<p></p>
<p>In 23 healthy subjects, a single dose of 7 Renagel capsules did not alter
the absorption of a single oral dose of iron as 200 mg exsiccated ferrous sulfate
tablet.</p>
<p>
Â 
</p>
<p></p>
<p> There are no empirical data on avoiding drug interactions between
Renagel<span class="Sup">Â®</span> and most concomitant drugs. During postmarketing
experience, very rare cases of increased thyroid stimulating hormone (TSH) levels
have been reported in patients co-administered sevelamer hydrochloride and
levothyroxine. Closer monitoring of TSH levels is therefore recommended in
patients receiving both medications. </p>
<p>When administering an oral medication where a reduction in the
bioavailability of that medication would have a clinically significant effect on
its safety or efficacy, the drug should be administered at least one hour before
or three hours after Renagel, or the physician should consider monitoring blood
levels of the drug. Patients taking anti-arrhythmic medications for the control of
<span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> and anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> medications for the control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> disorders were
excluded from the clinical trials. Special precautions should be taken when
prescribing Renagel to patients also taking these medications.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<p> Pregnancy Category C: The effect of Renagel on the absorption of
vitamins and other nutrients has not been studied in pregnant women. Requirements
for vitamins and other nutrients are increased in pregnancy. In pregnant rats
given doses of Renagel during organogenesis, reduced or irregular ossification of
fetal bones, probably due to a reduced absorption of fat-soluble vitamin D,
occurred. In pregnant rabbits given oral doses of Renagel by gavage during
organogenesis, an increase of early resorptions occurred. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[See </span></span><a href="#cc23b3c3-9818-4840-a9e7-98ee77d93dc0"> NONCLINICAL TOXICOLOGY
(13.1)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
<p>
Â 
</p>
<p></p>
<p> No Renagel treatment-related effects on labor and delivery were seen in
animal studies. The effects of Renagel on labor and delivery in
humansÂ are not known. <span class="Italics"><span class="Emphasis"><span class="Italics"><span class="Emphasis">[See </span></span><a href="#cc23b3c3-9818-4840-a9e7-98ee77d93dc0"> NONCLINICAL TOXICOLOGY
(13.1)</a><span class="Italics"><span class="Emphasis">]</span></span></span></span></p>
<p>
Â 
</p>
<p></p>
<p>The safety and efficacy of Renagel has not been established in pediatric
patients.</p>
<p>
Â 
</p>
<p></p>
<p>Clinical studies of Renagel did not include sufficient numbers of
subjects aged 65 and over to determine whether they respond differently from
younger subjects. Other reported clinical experience has not identified
differences in responses between the elderly and younger patients. In general,
dose selection for an elderly patient should be cautious, usually starting at the
low end of the dosing range.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>Renagel has been given to normal healthy volunteers in doses of up to 14
grams per day for eight days with no adverse effects. Renagel has been given in
average doses up to 13 grams per day to hemodialysis patients. There are no reports of
overdosage with Renagel in patients. Since Renagel is not absorbed, the risk of
systemic toxicity is low.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-10"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p> The active ingredient in Renagel Tablets is sevelamer hydrochloride, a
polymeric amine that binds phosphate and is meant for oral administration. Sevelamer
hydrochloride is poly(allylamine hydrochloride) crosslinked with epichlorohydrin in
which forty percent of the amines are protonated. It is known chemically as
poly(allylamine-<span class="Underline"><span class="Emphasis">co</span></span>-N,Nâ€™-diallyl-1,3-diamino-2-hydroxypropane) hydrochloride.
Sevelamer hydrochloride is hydrophilic, but insoluble in water. The structure is
represented in <a href="#MM280">Figure 1</a>. </p>
<p><span class="Bold"><span class="Emphasis">Figure 1. Chemical Structure of Sevelamer
Hydrochloride</span></span></p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2a373e4-110e-4f9a-9abe-e0c4374770d4&amp;name=MM1.jpg"></p>
<p>Â Â Â Â Â Â a, b = number of
primary amine
groupsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â a
+ b = 9</p>
<p>Â Â Â Â Â Â c = number of
crosslinking
groupsÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â c
= 1</p>
<p>Â Â Â Â Â Â n = fraction of
protonated
aminesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â n
= 0.4</p>
<p>Â Â Â Â Â Â m = large number
to indicate extended polymer network</p>
<p>The primary amine groups shown in the structure are derived directly from
poly(allylamine hydrochloride). The crosslinking groups consist of two secondary amine
groups derived from poly(allylamine hydrochloride) and one molecule of
epichlorohydrin.</p>
<p><span class="Bold"><span class="Emphasis"> Renagel<span class="Sup">Â®</span> Tablets: </span></span>Each film-coated tablet of Renagel contains either 800 mg or 400 mg of
sevelamer hydrochloride on an anhydrous basis. The inactive ingredients are
hypromellose, diacetylated monoglyceride, colloidal silicon dioxide, and stearic acid.
The tablet imprint contains iron oxide black ink. </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-11"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p> Patients with <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span> (CKD) on dialysis retain phosphorus and
can develop <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span>. High serum phosphorus can precipitate serum calcium
resulting in ectopic calcification. When the product of serum calcium and phosphorus
concentrations (Ca x P) exceeds 55 mg<span class="Sup">2</span>/dL<span class="Sup">2</span>, there is an
increased risk that ectopic calcification will occur. <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">Hyperphosphatemia</span> plays a role
in the development of secondary <span class="product-label-link" type="condition" conceptid="133729" conceptname="Hyperparathyroidism">hyperparathyroidism</span> in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. </p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="4065502" conceptname="Hyperphosphatemia">hyperphosphatemia</span> includes reduction in dietary intake of
phosphate, inhibition of intestinal phosphate absorption with phosphate binders, and
removal of phosphate with dialysis. Renagel taken with meals has been shown to
decrease serum phosphorus concentrations in patients with CKD who are on
dialysis.</p>
<p>
Â 
</p>
<p></p>
<p>Renagel contains sevelamer hydrochloride, a non-absorbed binding
crosslinked polymer. It contains multiple amines separated by one carbon from the
polymer backbone. These amines exist in a protonated form in the intestine and
interact with phosphate molecules through ionic and hydrogen bonding. By binding
phosphate in the dietary tract and decreasing absorption, sevelamer hydrochloride
lowers the phosphate concentration in the serum.</p>
<p>
Â 
</p>
<p></p>
<p> In addition to effects on serum phosphate levels, sevelamer
hydrochloride has been shown to bind bile acids <span class="Italics"><span class="Emphasis">in vitro</span></span> and <span class="Italics"><span class="Emphasis">in vivo</span></span> in experimental animal models. Bile acid binding by ion exchange resins
is a well-established method of lowering blood <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. Because sevelamer
binds bile acids, it may interfere with normal fat absorption and thus may reduce
absorption of fat-soluble vitamins such as A, D and K. In clinical trials of
sevelamer hydrochloride, both the mean total and LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> declined by
15-31%. This effect is observed after 2 weeks. Triglycerides, HDL
<span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> and albumin did not change. </p>
<p>
Â 
</p>
<p></p>
<p> A <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> balance study using <span class="Sup">14</span>C-sevelamer hydrochloride in 16
healthy male and female volunteers showed that sevelamer hydrochloride is not
systemically absorbed. No absorption studies have been performed in patients with
<span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>. </p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Standard lifetime carcinogenicity bioassays were conducted in mice and
rats. Rats were given sevelamer hydrochloride by diet at 0.3, 1, or 3 g/kg/day.
There was an increased incidence of urinary bladder transitional cell <span class="product-label-link" type="condition" conceptid="4034142" conceptname="Papilloma">papilloma</span> in
male rats of the high dose group (human equivalent dose twice the maximum clinical
trial dose of 13 g). Mice received dietary administration of sevelamer
hydrochloride at doses of up to 9 g/kg/day (human equivalent dose 3 times the
maximum clinical trial dose). There was no increased incidence of tumors observed
in mice.</p>
<p> In an <span class="Italics"><span class="Emphasis">in vitro</span></span> mammalian cytogenetic test with metabolic activation, sevelamer
hydrochloride caused a statistically significant increase in the number of
structural chromosome aberrations. Sevelamer hydrochloride was not mutagenic in
the Ames bacterial mutation assay. </p>
<p>Sevelamer hydrochloride did not impair the fertility of male or female
rats in a dietary administration study in which the females were treated from 14
days prior to mating through gestation and the males were treated for 28 days
prior to mating. The highest dose in this study was 4.5 g/kg/day (human equivalent
dose 3 times the maximum clinical trial dose of 13 g).</p>
<p>In pregnant rats given dietary doses of 0.5, 1.5 or 4.5 g/kg/day of
sevelamer hydrochloride during organogenesis, reduced or irregular ossification of
fetal bones, probably due to a reduced absorption of fat-soluble vitamin D,
occurred in mid- and high-dose groups (human equivalent doses less than the
maximum clinical trial dose of 13 g). In pregnant rabbits given oral doses of 100,
500 or 1000 mg/kg/day of sevelamer hydrochloride by gavage during organogenesis,
an increase of early resorptions occurred in the high-dose group (human equivalent
dose twice the maximum clinical trial dose).</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-13"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p>The ability of Renagel to lower serum phosphorus in CKD patients on dialysis
was demonstrated in six clinical trials: one double-blind placebo controlled 2-week
study (Renagel N=24); two open-label uncontrolled 8-week studies (Renagel N=220) and
three active-controlled open-label studies with treatment durations of 8 to 52 weeks
(Renagel N=256). Three of the active-controlled studies are described here. One is a
crossover study with two 8-week periods comparing Renagel to an active-control. The
second is a 52-week parallel study comparing Renagel with active-control. The third is
a 12-week parallel study comparing Renagel and active-control in peritoneal dialysis
patients.</p>
<p>
Â 
</p>
<p></p>
<p> Eighty-four CKD patients on hemodialysis who were hyperphosphatemic
(serum phosphorus &gt; 6.0 mg/dL) following a two-week phosphate binder
washout period received Renagel and active-control for eight weeks each in random
order. Treatment periods were separated by a two-week phosphate binder washout
period. Patients started on treatment three times per day with meals. Over each
eight-week treatment period, at three separate time points the dose of Renagel
could be titrated up 1 capsule or tablet per meal (3 per day) to control serum
phosphorus, the dose of active-control could also be altered to attain phosphate
control. Both treatments significantly decreased mean serum phosphorus by about 2
mg/dL (<a href="#fcb9773c-a79b-4976-85b7-e3545f471acc">Table 4</a>). </p>
<a name="fcb9773c-a79b-4976-85b7-e3545f471acc"></a><table>
<caption><span>Table 4. Mean Serum Phosphorus (mg/dL) at Baseline and Endpoint</span></caption>
<col align="left" span="1">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"><br></th>
<th colspan="1">
Renagel<span class="Sup">Â®</span><br> (N=81) </th>
<th colspan="1">
Â Active-Control <br> (N=83) </th>
</tr>
<tr>
<td align="left"><p class="First">Baseline at End of Washout</p></td>
<td><p class="First">8.4</p></td>
<td><p class="First">8.0</p></td>
</tr>
<tr>
<td align="left"><p class="First">Endpoint</p></td>
<td><p class="First">6.4</p></td>
<td><p class="First">5.9</p></td>
</tr>
<tr class="Last">
<td align="left">
<p class="First">Change from Baseline at Endpoint</p>
<p>(95% Confidence Interval)</p>
</td>
<td>
<p class="First">-2.0<a href="#footnote-1">*</a></p>
<p>(-2.5, -1.5)</p>
</td>
<td>
<p class="First"> -2.1<a href="#footnote-2" class="Sup">2</a></p>
<p>(-2.6, -1.7)</p>
</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<p> The distribution of responses is shown in <a href="#MM350">FigureÂ 2 </a>. The distributions are similar for sevelamer
hydrochloride and active control. The median response is a reduction of about 2
mg/dL in both groups. About 50% of subjects have reductions between 1 and 3 mg/dL. </p>
<p><span class="Bold"><span class="Emphasis">Figure 2. Percentage of patients (Y-axis)
attaining a phosphorus reduction from baseline (mg/dL) at least as great as
the value of the X-axis. </span></span></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2a373e4-110e-4f9a-9abe-e0c4374770d4&amp;name=MM2.jpg"></p>
<p>Average daily Renagel dose at the end of treatment was 4.9 g (range of
0.0 to 12.6 g).</p>
<p>
Â 
</p>
<p></p>
<p> Two hundred CKD patients on hemodialysis who were hyperphosphatemic
(serum phosphorus &gt;5.5 mg/dL) following a two-week phosphate binder washout
period were randomized to receive Renagel 800 mg tablets (N=99) or an
active-control (N=101). The two treatments produced similar decreases in serum
phosphorus. At week 52, using last-observation-carried-forward, Renagel and
active-control both significantly decreased mean serum
phosphorusÂ (<a href="#bff8bfec-c053-4c90-be5c-aa4686cdf649">Table 5</a>). </p>
<a name="bff8bfec-c053-4c90-be5c-aa4686cdf649"></a><table>
<caption><span>Table 5. Mean Serum Phosphorus (mg/dL) and Ion Product at Baseline and
Change from Baseline to End of Treatment</span></caption>
<col align="left" span="1">
<col align="left" span="1">
<col align="left" span="1">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1"><br></th>
<th align="left" colspan="1">
Renagel<span class="Sup">Â®</span><br> (N=94) </th>
<th align="left" colspan="1">
Active-Control<br> (N=98) </th>
</tr>
<tr>
<td align="left">
<p class="First">Phosphorus</p>
<p>Baseline</p>
<p>Change from Baseline at Endpoint</p>
</td>
<td align="left">
<br><p class="First">7.5</p>
<p>-2.1</p>
</td>
<td align="left">
<br><p class="First">7.3</p>
<p>-1.8</p>
</td>
</tr>
<tr class="Last">
<td align="left">
<p class="First">Ca x Phosphorus Ion Product</p>
<p>Baseline</p>
<p>Change from Baseline at Endpoint</p>
</td>
<td align="left">
<br><p class="First">Â 70.5 </p>
<p>-19.4</p>
</td>
<td align="left">
<br><p class="First">Â 68.4 </p>
<p>-14.2</p>
</td>
</tr>
</tbody>
</table>
<p>Sixty-one percent of Renagel patients and 73% of the control
patients completed the full 52 weeks of treatment.</p>
<p><a href="#MM360">Figure 3</a>, a plot of the phosphorus change from
baseline for the completers, illustrates the durability of response for patients
who are able to remain on treatment. </p>
<p><span class="Bold"><span class="Emphasis">Figure 3. Mean Phosphorus Change from Baseline for
Patients who Completed 52 Weeks of Treatment </span></span></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2a373e4-110e-4f9a-9abe-e0c4374770d4&amp;name=MM3.jpg"></p>
<p>Average daily Renagel dose at the end of treatment was 6.5 g (range of
0.8 to 13 g).</p>
<p>
Â 
</p>
<p></p>
<p> One hundred and forty-three patients on peritoneal dialysis who were
hyperphosphatemic (serum phosphorus &gt; 5.5 mg/dL) following a two-week
phosphate binder washout period were randomized to receive
Renagel<span class="Sup">Â®</span> (N=97) or active-control (N=46) open label for 12
weeks. Average daily Renagel dose at the end of treatment was 5.9 g (range 0.8 to
14.3 g). There were statistically significant changes in serum phosphorus
(p&lt;0.001) for Renagel (-1.6 mg/dL from baseline of 7.5 mg/dL), similar to
the active-control. </p>
<p>
Â 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>p&lt;0.0001, within treatment group
comparison</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p> Renagel<span class="Sup">Â®</span> 800 mg Tablets are supplied as oval,
film-coated, compressed tablets, imprinted with â€œRENAGEL 800â€?
containing 800 mg of sevelamer hydrochloride on an anhydrous basis, hypromellose,
diacetylated monoglyceride, colloidal silicon dioxide, and stearic acid.
Renagel<span class="Sup">Â®</span> 800 mg Tablets are packaged in bottles of 180 tablets. </p>
<p> Renagel<span class="Sup">Â®</span> 400 mg Tablets are supplied as oval,
film-coated, compressed tablets, imprinted with â€œRENAGEL 400â€?
containing 400 mg of sevelamer hydrochloride on an anhydrous basis, hypromellose,
diacetylated monoglyceride, colloidal silicon dioxide, and stearic acid.
Renagel<span class="Sup">Â®</span> 400 mg Tablets are packaged in bottles of 360 tablets. </p>
<p>1 Bottle of 30 ct 800 mg Tablets (NDC 58468-0021-3)</p>
<p>1 Bottle of 180 ct 800 mg Tablets (NDC 58468-0021-1)</p>
<p>1 Bottle of 360 ct 400 mg Tablets (NDC 58468-0020-1)</p>
<p><span class="Bold"><span class="Emphasis"> Storage </span></span>Store at 25Â°C (77Â°F): excursions permitted to
15-30Â°C (59-86Â°F). </p>
<p> Do not use Renagel<span class="Sup">Â®</span> after the expiration date on the
bottle. </p>
<p>[See USP controlled room temperature]</p>
<p>Protect from moisture.</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-15"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"></p>
<p>The prescriber should inform patients to take Renagel with meals and
adhere to their prescribed diets. Instructions should be given on concomitant
medications that should be dosed apart from Renagel. </p>
<p>
Â 
</p>
<p></p>
<p>Renagel may cause <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> that if left untreated, may lead to severe
complications. Patients should be cautioned to report new onset or worsening of
existing <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> promptly to their physician.</p>
<p>Distributed by: </p>
<p>Genzyme Corporation</p>
<p>500 Kendall Street</p>
<p>Cambridge, MA 02142 USA</p>
<p>
Â 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Renagel </p>
<p><br></p>
<p>GENERIC: Renagel</p>
<p><br></p>
<p>DOSAGE: TABLET</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 52125-435-02</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>SEVELAMER HYDROCHLORIDE 800mg in 1</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>COLLOIDAL SILICON DIOXIDE</li>
<li>FERROSOFERRIC OXIDE </li>
<li>HYPROMELLOSE 2910 (15 MPA.S)</li>
<li>PROPYLENE GLYCOL</li>
<li>HYPROMELLOSE 2910 (5 MPA.S)</li>
<li>STEARIC ACID</li>
<li>ISOPROPYL ALCOHOL</li>
<li>WATER</li>
</ul>
<p><br></p>
<p>COLOR: white</p>
<p><br></p>
<p>SHAPE: OVAL</p>
<p><br></p>
<p>SCORE: No score</p>
<p><br></p>
<p>SIZE: 19 mm</p>
<p><br></p>
<p>IMPRINT: RENAGEL;800</p>
<p><br></p>
<p>PACKAGING: 30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</p>
<p><br></p>
<p><br></p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2a373e4-110e-4f9a-9abe-e0c4374770d4&amp;name=MM4.jpg"></p>
<p><img alt="MM5" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=b2a373e4-110e-4f9a-9abe-e0c4374770d4&amp;name=MM5.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>RENAGELÂ 		
					</strong><br><span class="contentTableReg">renagel tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-435(NDC:58468-0021)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SEVELAMER HYDROCHLORIDE</strong> (SEVELAMER) </td>
<td class="formItem">SEVELAMER HYDROCHLORIDE</td>
<td class="formItem">800Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COLLOIDAL SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FERROSOFERRIC OXIDE </strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (15 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYPROMELLOSE 2910 (5 MPA.S)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ISOPROPYL ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (TABLET) </td>
<td class="formLabel">Size</td>
<td class="formItem">19mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">RENAGEL;800</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-435-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021179</td>
<td class="formItem">05/15/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>db55e9fb-13de-40b1-9a08-27aafc806242</div>
<div>Set id: b2a373e4-110e-4f9a-9abe-e0c4374770d4</div>
<div>Version: 1</div>
<div>Effective Time: 20130515</div>
</div>
</div>Â <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
